Literature DB >> 19055369

Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer.

Li Yan1, Sarah Tonack, Richard Smith, Susanna Dodd, Rosalind E Jenkins, Neil Kitteringham, William Greenhalf, Paula Ghaneh, John P Neoptolemos, Eithne Costello.   

Abstract

It is well established that variation in sampling, processing and storage protocols can alter the levels of potential biomarkers in serum and plasma. Here, using pancreatic cancer as an example, we demonstrate that consideration of clinical parameters related to the patient's illness is equally important when seeking cancer-specific biomarkers. Bile duct-obstruction is a feature of pancreatic disease that can cause jaundice. Comparing patients with pancreatic cancer, chronic pancreatitis or biliary duct obstruction, we observed that the plasma levels of apolipoprotein A1, transthyretin, and apolipoprotein E, when examined in isolation, were each associated with pancreatic cancer. However, when the effect of bile duct obstruction was considered, only transthyretin levels were independently associated with cancer likelihood. Our results demonstrate the importance of accounting for disease-related confounding factors when analyzing data for the detection of cancer biomarkers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19055369     DOI: 10.1021/pr800451h

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  20 in total

1.  Biomarker discovery and clinical proteomics.

Authors:  Jerzy Silberring; Pawel Ciborowski
Journal:  Trends Analyt Chem       Date:  2010-02-01       Impact factor: 12.296

2.  Proteomic analyses of human plasma: Venus versus Mars.

Authors:  Christopher C Silliman; Monika Dzieciatkowska; Ernest E Moore; Marguerite R Kelher; Anirban Banerjee; Xiayuan Liang; Kevin J Land; Kirk C Hansen
Journal:  Transfusion       Date:  2011-08-31       Impact factor: 3.157

3.  Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.

Authors:  Jungsun Kim; William R Bamlet; Ann L Oberg; Kari G Chaffee; Greg Donahue; Xing-Jun Cao; Suresh Chari; Benjamin A Garcia; Gloria M Petersen; Kenneth S Zaret
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

Review 4.  Early detection of pancreatic cancer.

Authors:  Stephen P Pereira; Lucy Oldfield; Alexander Ney; Phil A Hart; Margaret G Keane; Stephen J Pandol; Debiao Li; William Greenhalf; Christie Y Jeon; Eugene J Koay; Christopher V Almario; Christopher Halloran; Anne Marie Lennon; Eithne Costello
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-02

Review 5.  Proteomics analysis of bodily fluids in pancreatic cancer.

Authors:  Sheng Pan; Teresa A Brentnall; Ru Chen
Journal:  Proteomics       Date:  2015-04-27       Impact factor: 3.984

6.  Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas.

Authors:  Sukhwinder Kaur; Michael J Baine; Sushovan Guha; Nobuo Ochi; Subhankar Chakraborty; Kavita Mallya; Colleen Thomas; Julia Crook; Michael B Wallace; Timothy A Woodward; Maneesh Jain; Shailender Singh; Aaron R Sasson; Verna Skinner; Massimo Raimondo; Surinder K Batra
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

7.  Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.

Authors:  Jiong Chen; Long-Jiang Chen; Yun-Lian Xia; Hang-Cheng Zhou; Ren-Bao Yang; Wen Wu; Yin Lu; Li-Wei Hu; Yue Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-02       Impact factor: 4.553

8.  Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.

Authors:  Claire Jenkinson; Victoria L Elliott; Anthony Evans; Lucy Oldfield; Rosalind E Jenkins; Darragh P O'Brien; Sophia Apostolidou; Aleksandra Gentry-Maharaj; Evangelia-O Fourkala; Ian J Jacobs; Usha Menon; Trevor Cox; Fiona Campbell; Stephen P Pereira; David A Tuveson; B Kevin Park; William Greenhalf; Robert Sutton; John F Timms; John P Neoptolemos; Eithne Costello
Journal:  Clin Cancer Res       Date:  2015-11-16       Impact factor: 12.531

9.  Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies.

Authors:  Christoph Schröder; Anette Jacob; Sarah Tonack; Tomasz P Radon; Martin Sill; Manuela Zucknick; Sven Rüffer; Eithne Costello; John P Neoptolemos; Tatjana Crnogorac-Jurcevic; Andrea Bauer; Kurt Fellenberg; Jörg D Hoheisel
Journal:  Mol Cell Proteomics       Date:  2010-02-16       Impact factor: 5.911

10.  Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

Authors:  C Dive; R A Smith; E Garner; T Ward; S St George-Smith; F Campbell; W Greenhalf; P Ghaneh; J P Neoptolemos
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.